Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 5/20 | 0.40 |
| ▸ | ABL1 | P00519 | 2/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | FDPS | P14324 | 2/20 | 0.39 |
| ▸ | IGF1R | P08069 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14270718 | 0.84 | NOS3 (0.48) | MAPK14NR3C2MAPK10HRH4FDPS | |
| SCHEMBL22388259 | 0.82 | KDM4E (0.43) | MAPK14NR3C2MAPK10HRH4FDPS | |
| SCHEMBL17372006 | 0.82 | LOXL2 (0.47) | MAPK14NR3C2MAPK10HRH4IGF1R | |
| Hydrochloric Acid SCHEMBL31330323 | 0.81 | MAPK14 (0.40) | MAPK14NR3C2MAPK10HRH4FDPS | |
| SCHEMBL4306508 | 0.79 | RECQL (0.52) | RECQLNR3C2ABL1 | |
| Hydrochloric Acid SCHEMBL2302210 | 0.78 | IGF1R (0.39) | MAPK14NR3C2MAPK10HRH4FDPS | |
| SCHEMBL23021737 | 0.76 | RECQL (0.48) | RECQLNR3C2ABL1IGF1R | |
| SCHEMBL5070476 | 0.76 | RECQL (0.52) | RECQLNR3C2ABL1 | |
| SCHEMBL26547688 | 0.76 | MAPK14 (0.42) | MAPK14MAPK10HRH4FDPS | |
| SCHEMBL13003443 | 0.74 | RECQL (0.46) | RECQLNR3C2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158025-A1 | GALACTOKINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH | 2023-05-25 | — | — | US | disclosed |
| EP-2376478-B1 | PYRIDYLOXYINDOLES INHIBITORS OF VEGF-R2 AND USE THEREOF FOR TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2017-04-19 | — | — | EP | disclosed |
| EP-2376478-B1 | PYRIDYLOXYINDOLES INHIBITORS OF VEGF-R2 AND USE THEREOF FOR TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2017-04-19 | — | — | EP | disclosed |
| CN-103193773-B | Pyridyloxyindoles inhibitors of VEGF-R2 and their use for treating diseases | NOVARTIS AG | 2014-12-10 | — | — | CN | disclosed |
| CN-102307870-B | Pyridyloxyindoles inhibitors of VEGF-R2 and their use for treating diseases | NOVARTIS AG | 2014-06-18 | — | — | CN | disclosed |
| US-8541432-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2013-09-24 | — | — | US | disclosed |
| US-8541432-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2013-09-24 | — | — | US | disclosed |
| US-8541432-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2013-09-24 | — | — | US | disclosed |
| US-8501756-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2013-08-06 | — | — | US | disclosed |
| US-8501756-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2013-08-06 | — | — | US | disclosed |
| US-8242125-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2012-08-14 | — | — | US | disclosed |
| US-8242125-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2012-08-14 | — | — | US | disclosed |
| US-8242125-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2012-08-14 | — | — | US | disclosed |
| CN-102307870-A | Pyridyloxyindoles inhibitors of VEGF-R2 and their use for treating diseases | NOVARTIS AG | 2012-01-04 | — | — | CN | disclosed |
| EP-2376478-A2 | PYRIDYLOXYINDOLES INHIBITORS OF VEGF-R2 AND USE THEREOF FOR TREATMENT OF DISEASE | Novartis AG (CH) | 2011-10-19 | — | — | EP | disclosed |
| US-20100168082-A1 | Heterobicyclic Carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2010-07-01 | — | — | US | disclosed |
| US-20100168082-A1 | Heterobicyclic Carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2010-07-01 | — | — | US | disclosed |
| US-20100168082-A1 | Heterobicyclic Carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2010-07-01 | — | — | US | disclosed |
| WO-2010066684-A2 | Pyridyloxyindoles Inhibitors of VEGF-R2 and Use Thereof for Treatment of Disease | NOVARTIS AG (CH) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010066684-A2 | Pyridyloxyindoles Inhibitors of VEGF-R2 and Use Thereof for Treatment of Disease | NOVARTIS AG (CH) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158025-A1 | GALACTOKINASE INHIBITORS | GALK1, GCK, GCKR | RECQL 4444/4885MAPK14 324/4885NR3C2 4191/4885 |
| US-20100168082-A1 | Heterobicyclic Carboxamides as inhibitors for kinases | CDK2, PHKG1, PHKG2 | RECQL 2817/4885MAPK14 145/4885NR3C2 3986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.